Merck’s decision to reduce the price of cholesterol-lowering generic simvastatin (Zocor drug) in the face of first-time generic competition from Teva Pharmaceuticals may be red meat for the congressional advocates of faster approval of generic versions of both chemical and biotech innovator drugs. And those forces may get a bigger boost still when Sandoz announces [...]